Hydroxychloroquine takes another hit in failed small-scale COVID-19 study

Question mark background
Despite President Donald Trump's backing, hydroxychloroquine has shown mixed results in treating COVID-19. (Pixabay)

Antimalarial hydroxychloroquine has raked in support as a potential wonder drug to treat COVID-19, with even President Donald Trump touting it as a possible "game changer." But small-scale studies have been less than definitive on the drug's chances—and new data haven't cleared matters up much.

A U.S. Department of Veterans Affairs (VA) study (PDF) found that severe COVID-19 patients treated with antimalarial hydroxychloroquine alone or in combination with antibiotic azithromycin showed "no evidence" of reduced risk of death or mechanical ventilation over supportive care, according to data posted Tuesday. 

In a small-scale analysis of 368 COVID-19 patients treated in VA hospitals, researchers found there was no significant difference in ventilation risk for all three cohorts. Meanwhile, patients treated with hydroxychloroquine alone showed a significantly higher risk of all-cause mortality over either supportive care of a combination of hydroxychloroquine and azithromycin. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

The researchers noted their analysis was not randomized nor controlled and cautioned patience for several ongoing clinical studies to read out before drawing conclusions on hydroxychloroquine's use for COVID-19. 

RELATED: Did chloroquine really fail a COVID-19 study—or was the trial design to blame?

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.